16:23:36 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-21 Bokslutskommuniké 2024
2024-11-15 Kvartalsrapport 2024-Q3
2024-08-23 Kvartalsrapport 2024-Q2
2024-06-28 Årsstämma 2024
2024-05-29 Kvartalsrapport 2024-Q1
2024-05-17 X-dag ordinarie utdelning CLS B 0.00 SEK
2024-04-25 Split CLS B 200:1
2024-04-12 Extra Bolagsstämma 2024
2024-02-23 Bokslutskommuniké 2023
2023-11-17 Kvartalsrapport 2023-Q3
2023-08-25 Kvartalsrapport 2023-Q2
2023-06-29 Årsstämma 2023
2023-06-22 X-dag ordinarie utdelning CLS B 0.00 SEK
2023-06-08 Extra Bolagsstämma 2023
2023-05-25 Kvartalsrapport 2023-Q1
2023-02-23 Bokslutskommuniké 2022
2022-11-22 Extra Bolagsstämma 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-06-29 X-dag ordinarie utdelning CLS B 0.00 SEK
2022-06-28 Årsstämma 2022
2022-05-19 Kvartalsrapport 2022-Q1
2022-02-24 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-08-24 Kvartalsrapport 2021-Q2
2021-06-29 X-dag ordinarie utdelning CLS B 0.00 SEK
2021-06-28 Årsstämma 2021
2021-05-19 Kvartalsrapport 2021-Q1
2021-03-31 Extra Bolagsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-06-12 X-dag ordinarie utdelning CLS B 0.00 SEK
2020-06-11 Årsstämma 2020
2020-05-28 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-21 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-06-12 X-dag ordinarie utdelning CLS B 0.00 SEK
2019-05-17 Årsstämma 2019
2019-05-16 Kvartalsrapport 2019-Q1
2019-03-18 Extra Bolagsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-11-22 Kvartalsrapport 2018-Q3
2018-08-23 Kvartalsrapport 2018-Q2
2018-06-20 Årsstämma 2018
2018-06-14 X-dag ordinarie utdelning CLS B 0.00 SEK
2018-05-24 Kvartalsrapport 2018-Q1
2018-05-18 Extra Bolagsstämma 2018
2018-02-22 Bokslutskommuniké 2017
2017-11-16 Kvartalsrapport 2017-Q3
2017-07-17 Kvartalsrapport 2017-Q2
2017-06-28 X-dag ordinarie utdelning CLS B 0.00 SEK
2017-06-27 Årsstämma 2017
2017-05-18 Kvartalsrapport 2017-Q1
2017-01-31 Bokslutskommuniké 2016
2017-01-20 Extra Bolagsstämma 2017
2016-11-17 Kvartalsrapport 2016-Q3
2016-08-18 Kvartalsrapport 2016-Q2
2016-06-16 Årsstämma 2016
2016-05-19 Kvartalsrapport 2016-Q1
2016-02-21 Bokslutskommuniké 2015
2015-11-19 Kvartalsrapport 2015-Q3
2015-08-20 Kvartalsrapport 2015-Q2
2015-06-12 X-dag ordinarie utdelning CLS B 0.00 SEK
2015-06-11 Årsstämma 2015
2015-05-21 Kvartalsrapport 2015-Q1
2015-02-23 Bokslutskommuniké 2014
2014-11-14 Kvartalsrapport 2014-Q3
2014-08-20 Kvartalsrapport 2014-Q2
2014-06-18 X-dag ordinarie utdelning CLS B 0.00 SEK
2014-06-17 Årsstämma 2014
2014-05-22 Kvartalsrapport 2014-Q1
2014-02-24 Bokslutskommuniké 2013
2013-11-22 Kvartalsrapport 2013-Q3
2013-09-19 Extra Bolagsstämma 2013
2013-08-20 Kvartalsrapport 2013-Q2
2013-06-10 X-dag ordinarie utdelning CLS B 0.00 SEK
2013-06-07 Årsstämma 2013
2013-05-24 Kvartalsrapport 2013-Q1
2013-02-25 Bokslutskommuniké 2012
2012-11-23 Kvartalsrapport 2012-Q3
2012-08-24 Kvartalsrapport 2012-Q2
2012-06-08 X-dag ordinarie utdelning CLS B 0.00 SEK
2012-06-07 Årsstämma 2012
2012-04-20 Kvartalsrapport 2012-Q1
2012-01-09 Bokslutskommuniké 2011
2012-01-04 Extra Bolagsstämma 2012
2011-11-21 Kvartalsrapport 2011-Q3
2011-09-26 Kapitalmarknadsdag 2010
2011-08-22 Kvartalsrapport 2011-Q2
2011-06-10 Årsstämma 2011
2011-05-20 Kvartalsrapport 2011-Q1
2011-02-24 Bokslutskommuniké 2010
2010-11-24 Kvartalsrapport 2010-Q3
2010-08-25 Kvartalsrapport 2010-Q2
2010-05-28 X-dag ordinarie utdelning CLS B 0.00 SEK
2010-05-26 Kvartalsrapport 2010-Q1
2010-02-26 Bokslutskommuniké 2009
2009-11-30 Kvartalsrapport 2009-Q3

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Clinical Laserthermia Systems är verksamt inom medicinteknik. Bolagets vision är att utveckla och effektivisera behandlingen av solida cancertumörer, där bolaget är försäljare av sterila patientkit. Produkterna används i diverse cancerbehandlingar som vid behandling av malignt melanom, samt cancer i lungor, lever och bukspottkörtel. Bolaget grundades 2006 och har sitt huvudkontor i Lund.
2023-09-07 14:49:22

WASHINGTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- CLS Americas, a leading provider of office-based, focal laser ablation systems in the US urology market, today announced it will exhibit its TRANBERG‚ĄĘ Thermal Therapy System for focal laser ablation at the Focal Therapy Society Annual Meeting 2023 being held this September 7-9, 2023 in Washington, DC. The TRANBERG system is designed to work with multiple MR/US fusion image guidance systems for precise and accurate tumor ablation in a minimally invasive, outpatient setting in a urology office or clinic. The system is FDA 510(k) cleared for soft tissue ablation in a urology setting.

In the US, over one million prostate biopsies are performed every year leading to a diagnosis of prostate cancer for almost 250,000 men. Compared to other focal therapies, focal laser ablation therapy has demonstrated higher levels of precision and accuracy with lower risk of side effects, such as erectile dysfunction and urinary incontinence.

‚ÄúCLS Americas is pleased to exhibit it‚Äôs latest TRANBERG focal laser ablation system at this year‚Äôs Focal Therapy Society 2023 Conference,‚ÄĚ stated Michael Magnani, president of CLS Americas. ‚ÄúIn addition to our various feasibility studies, TRANBERG is now commercially available for purchase or via our Mobile Services Provider (MSP) Agreement, a bundled service offering, with consumable accessories, training, and on-site clinical and technical staff support to physicians and staff during procedures. We are excited to offer this safe, minimally invasive, outpatient treatment to urology offices and clinics.‚ÄĚ

TRANBERG‚ĄĘ Thermal Therapy System
The TRANBERG Thermal Therapy System can be configured for MR/US fusion-guided procedures using real-time tissue temperature measurements for precise therapy and ablation control. It includes a desk-top mobile laser unit, innovative non-cooled laser applicators, tissue temperature probes, and procedure-specific accessories. The TRANBERG system can be deployed in either a transperineal or transrectal approach. The TRANBERG system is 510(k) cleared for soft tissue ablation, such as prostate.

About CLS Americas
Clinical Laserthermia Systems Americas Inc, based in Irvine, CA, is responsible for the sales, commercial development, operations and clinical support for the TRANBERG‚ĄĘ Thermal Therapy System and accessories for the US urology market. The powerful system provides minimally invasive, high precision, focal laser ablation using MR or MR US Fusion for image guidance and has received FDA 510 (k) clearance in the US for soft tissue ablation, such as prostate.

CLS Americas is a subsidiary of Clinical Laserthermia Systems AB (publ) headquartered in Lund, Sweden. which has subsidiaries in Germany, the US and Singapore.  For more information about CLS, please visit the Company's website: www.clinicallaser.com.  CLS Americas Contact:  Phone: +1 (949) 504-5440, E-mail: contact-us@clinicallaser.com.